-
Something wrong with this record ?
Mephedrone (4-Methylmethcathinone): Acute Behavioral Effects, Hyperthermic, and Pharmacokinetic Profile in Rats
K. Šíchová, N. Pinterová, M. Židková, RR. Horsley, E. Lhotková, K. Štefková, Č. Vejmola, L. Uttl, M. Balíková, M. Kuchař, T. Páleníček,
Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2009
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- Publication type
- Journal Article MeSH
Mephedrone (MEPH) is a synthetic cathinone derivative with effects that mimic MDMA and/or cocaine. Our study in male Wistar rats provides detailed investigations of MEPH's and its primary metabolite nor-mephedrone's (nor-MEPH) pharmacokinetics and bio-distribution to four different substrates (serum, brain, lungs, and liver), as well as comparative analysis of their effects on locomotion [open field test (OFT)] and sensorimotor gating [prepulse inhibition of acoustic startle reaction (PPI ASR)]. Furthermore, in order to mimic the crowded condition where MEPH is typically taken (e.g., clubs), the acute effect of MEPH on thermoregulation in singly- and group-housed rats was evaluated. Pharmacokinetics of MEPH and nor-MEPH after MEPH (5 mg/kg, sc.) were analyzed over 8 h using liquid chromatography with mass spectrometry. MEPH (2.5, 5, or 20 mg/kg, sc.) and nor-MEPH (5 mg/kg, sc.) were administered 5 or 40 min before the behavioral testing in the OFT and PPI ASR; locomotion and its spatial distribution, ASR, habituation and PPI itself were quantified. The effect of MEPH on rectal temperature was measured after 5 and 20 mg/kg, sc. Both MEPH and nor-MEPH were detected in all substrates, with the highest levels detected in lungs. Mean brain: serum ratios were 1:1.19 (MEPH) and 1:1.91 (nor-MEPH), maximum concentrations were observed at 30 min; at 2 and 4 h after administration, nor-MEPH concentrations were higher compared to the parent drug. While neither of the drugs disrupted PPI, both increased locomotion and affected its spatial distribution. The effects of MEPH were dose dependent, rapid, and short-lasting, and the intensity of locomotor stimulant effects was comparable between MEPH and nor-MEPH. Despite the disappearance of behavioral effects within 40 min after administration, MEPH induced rectal temperature elevations that persisted for 3 h even in singly housed rats. To conclude, we observed a robust, short-lasting, and most likely synergistic stimulatory effect of both drugs which corresponded to brain pharmacokinetics. The dissociation between the duration of behavioral and hyperthermic effects is indicative of the possible contribution of nor-MEPH or other biologically active metabolites. This temporal dissociation may be related to the risk of prolonged somatic toxicity when stimulatory effects are no longer present.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010054
- 003
- CZ-PrNML
- 005
- 20210316130125.0
- 007
- ta
- 008
- 180404s2018 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fpsyt.2017.00306 $2 doi
- 035 __
- $a (PubMed)29375408
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Šíchová, Klára $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic.
- 245 10
- $a Mephedrone (4-Methylmethcathinone): Acute Behavioral Effects, Hyperthermic, and Pharmacokinetic Profile in Rats / $c K. Šíchová, N. Pinterová, M. Židková, RR. Horsley, E. Lhotková, K. Štefková, Č. Vejmola, L. Uttl, M. Balíková, M. Kuchař, T. Páleníček,
- 520 9_
- $a Mephedrone (MEPH) is a synthetic cathinone derivative with effects that mimic MDMA and/or cocaine. Our study in male Wistar rats provides detailed investigations of MEPH's and its primary metabolite nor-mephedrone's (nor-MEPH) pharmacokinetics and bio-distribution to four different substrates (serum, brain, lungs, and liver), as well as comparative analysis of their effects on locomotion [open field test (OFT)] and sensorimotor gating [prepulse inhibition of acoustic startle reaction (PPI ASR)]. Furthermore, in order to mimic the crowded condition where MEPH is typically taken (e.g., clubs), the acute effect of MEPH on thermoregulation in singly- and group-housed rats was evaluated. Pharmacokinetics of MEPH and nor-MEPH after MEPH (5 mg/kg, sc.) were analyzed over 8 h using liquid chromatography with mass spectrometry. MEPH (2.5, 5, or 20 mg/kg, sc.) and nor-MEPH (5 mg/kg, sc.) were administered 5 or 40 min before the behavioral testing in the OFT and PPI ASR; locomotion and its spatial distribution, ASR, habituation and PPI itself were quantified. The effect of MEPH on rectal temperature was measured after 5 and 20 mg/kg, sc. Both MEPH and nor-MEPH were detected in all substrates, with the highest levels detected in lungs. Mean brain: serum ratios were 1:1.19 (MEPH) and 1:1.91 (nor-MEPH), maximum concentrations were observed at 30 min; at 2 and 4 h after administration, nor-MEPH concentrations were higher compared to the parent drug. While neither of the drugs disrupted PPI, both increased locomotion and affected its spatial distribution. The effects of MEPH were dose dependent, rapid, and short-lasting, and the intensity of locomotor stimulant effects was comparable between MEPH and nor-MEPH. Despite the disappearance of behavioral effects within 40 min after administration, MEPH induced rectal temperature elevations that persisted for 3 h even in singly housed rats. To conclude, we observed a robust, short-lasting, and most likely synergistic stimulatory effect of both drugs which corresponded to brain pharmacokinetics. The dissociation between the duration of behavioral and hyperthermic effects is indicative of the possible contribution of nor-MEPH or other biologically active metabolites. This temporal dissociation may be related to the risk of prolonged somatic toxicity when stimulatory effects are no longer present.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pinterová, Nikola $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic. Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Židková, Monika $u Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Horsley, Rachel R $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic.
- 700 1_
- $a Lhotková, Eva $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic.
- 700 1_
- $a Štefková, Kristýna $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic.
- 700 1_
- $a Vejmola, Čestmír $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic. Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Uttl, Libor $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic. Department of Physiology, Faculty of Science, Charles University, Prague, Czech Republic.
- 700 1_
- $a Balíková, Marie $u Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Kuchař, Martin $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic. Forensic Laboratory of Biologically Active Compounds, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic.
- 700 1_
- $a Páleníček, Tomáš $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic. Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
- 773 0_
- $w MED00174602 $t Frontiers in psychiatry $x 1664-0640 $g Roč. 8, č. - (2018), s. 306
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29375408 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20210316130121 $b ABA008
- 999 __
- $a ind $b bmc $g 1287539 $s 1006866
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 8 $c - $d 306 $e 2017 $i 1664-0640 $m Frontiers in psychiatry $n Front Psychiatry $x MED00174602
- LZP __
- $a Pubmed-20180404